227 related articles for article (PubMed ID: 24148180)
1. MiR-370 sensitizes chronic myeloid leukemia K562 cells to homoharringtonine by targeting Forkhead box M1.
Zhou M; Zeng J; Wang X; Guo Q; Huang T; Shen H; Fu Y; Wang L; Jia J; Chen C
J Transl Med; 2013 Oct; 11():265. PubMed ID: 24148180
[TBL] [Abstract][Full Text] [Related]
2. Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors.
Visani G; Russo D; Ottaviani E; Tosi P; Damiani D; Michelutti A; Manfroi S; Baccarani M; Tura S
Leukemia; 1997 May; 11(5):624-8. PubMed ID: 9180282
[TBL] [Abstract][Full Text] [Related]
3. Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines.
Wang Q; Ding W; Ding Y; Ma J; Qian Z; Shao J; Li Y
Oncotarget; 2017 Jun; 8(23):37594-37604. PubMed ID: 28410239
[TBL] [Abstract][Full Text] [Related]
4. A comparative proteomic study of Homoharringtonine-induced apoptosis in leukemia K562 cells.
Zhou X; Xu N; Li R; Xiao Y; Gao G; Lu Q; Ding L; Li L; Li Y; Du Q; Liu X
Leuk Lymphoma; 2015 Jul; 56(7):2162-9. PubMed ID: 25330443
[TBL] [Abstract][Full Text] [Related]
5. HPLC analysis of harringtonine and homoharringtonine in the needles of Cephalotaxus griffithii alkaloid fraction and cytotoxic activity on chronic myelogenous leukaemia K562 cell.
Moirangthem DS; Borah JC; Laishram S; Kalita MC; Talukdar NC
Nat Prod Res; 2014; 28(18):1503-6. PubMed ID: 24787645
[TBL] [Abstract][Full Text] [Related]
6. Induction of apoptosis by homoharringtonine in G1 phase human chronic myeloid leukemic cells.
Mai WY; Lin MF
Chin Med J (Engl); 2005 Mar; 118(6):487-92. PubMed ID: 15788130
[TBL] [Abstract][Full Text] [Related]
7. [Research Progress of Homoharringtonine Effect on IM-resistant Chronic Myelogenous Leukemia -Review].
Wang Q; Li YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):596-599. PubMed ID: 28446318
[TBL] [Abstract][Full Text] [Related]
8. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
Cancer; 2002 May; 94(10):2653-62. PubMed ID: 12173333
[TBL] [Abstract][Full Text] [Related]
9. Homoharringtonine binds to and increases myosin-9 in myeloid leukaemia.
Zhang T; Shen S; Zhu Z; Lu S; Yin X; Zheng J; Jin J
Br J Pharmacol; 2016 Jan; 173(1):212-21. PubMed ID: 26448459
[TBL] [Abstract][Full Text] [Related]
10. [Effects of RNA interference targeting hypoxia-inducible factor-1alpha (HIF-1alpha) on chemosensitivity of leukemia K562 cells towards homoharringtonine].
Li BZ; Zhuang WZ; Chen P; Fu JX
Ai Zheng; 2008 Jul; 27(7):723-8. PubMed ID: 18606065
[TBL] [Abstract][Full Text] [Related]
11. Homoharringtonine enhances the effect of imatinib on chronic myelogenous leukemia cells by downregulating ZFX.
Wu J; Wei B; Shi Y; Lu X; Ding Y; Wang C; Li Y
Mol Med Rep; 2019 Oct; 20(4):3233-3239. PubMed ID: 31432109
[TBL] [Abstract][Full Text] [Related]
12. Homoharringtonine induces apoptosis of endothelium and down-regulates VEGF expression of K562 cells.
Ye XJ; Lin MF
J Zhejiang Univ Sci; 2004 Feb; 5(2):230-4. PubMed ID: 14674038
[TBL] [Abstract][Full Text] [Related]
13. MiR-152-3p promotes the development of chronic myeloid leukemia by inhibiting p27.
Wang L; Wang Y; Lin J
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8789-8796. PubMed ID: 30575920
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice.
Chen Y; Hu Y; Michaels S; Segal D; Brown D; Li S
Leukemia; 2009 Aug; 23(8):1446-54. PubMed ID: 19322212
[TBL] [Abstract][Full Text] [Related]
15. Homoharringtonine promotes BCR‑ABL degradation through the p62‑mediated autophagy pathway.
Li S; Bo Z; Jiang Y; Song X; Wang C; Tong Y
Oncol Rep; 2020 Jan; 43(1):113-120. PubMed ID: 31789418
[TBL] [Abstract][Full Text] [Related]
16. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells.
Venturini L; Battmer K; Castoldi M; Schultheis B; Hochhaus A; Muckenthaler MU; Ganser A; Eder M; Scherr M
Blood; 2007 May; 109(10):4399-405. PubMed ID: 17284533
[TBL] [Abstract][Full Text] [Related]
17. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors.
Mancini M; De Santis S; Monaldi C; Bavaro L; Martelli M; Castagnetti F; Gugliotta G; Rosti G; Santucci MA; Martinelli G; Cavo M; Soverini S
J Exp Clin Cancer Res; 2019 May; 38(1):216. PubMed ID: 31122263
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
O'Brien S; Talpaz M; Cortes J; Shan J; Giles FJ; Faderl S; Thomas D; Garcia-Manero G; Mallard S; Beth M; Koller C; Kornblau S; Andreeff M; Murgo A; Keating M; Kantarjian HM
Cancer; 2002 Apr; 94(7):2024-32. PubMed ID: 11932905
[TBL] [Abstract][Full Text] [Related]
19. LncRNA HAND2-AS1 inhibits proliferation and promotes apoptosis of chronic myeloid leukemia cells by sponging with micRNA-1275.
Yang JR; Shi MX; Zeng Y
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2103-2111. PubMed ID: 30915755
[TBL] [Abstract][Full Text] [Related]
20. [Effect of Autophagy on Homoharringtonine-treated K562 Cells].
Lu XY; Ye LL; Shi YY; Ding YH; Li YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):412-417. PubMed ID: 28446285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
